Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorThazhath, S.en
dc.contributor.authorMarathe, C.en
dc.contributor.authorWu, T.en
dc.contributor.authorChang, J.en
dc.contributor.authorKhoo, J.en
dc.contributor.authorKuo, P.en
dc.contributor.authorChecklin, H.en
dc.contributor.authorBound, M.en
dc.contributor.authorRigda, R.en
dc.contributor.authorCrouch, B.en
dc.contributor.authorJones, K.en
dc.contributor.authorHorowitz, M.en
dc.contributor.authorRayner, C.en
dc.identifier.citationDiabetes, 2016; 65(1):269-275en
dc.description.abstractThe short-acting glucagon-like peptide 1 receptor agonist exenatide reduces postprandial glycemia, partly by slowing gastric emptying, although its impact on small intestinal function is unknown. In this study, 10 healthy subjects and 10 patients with type 2 diabetes received intravenous exenatide (7.5 μg) or saline (-30 to 240 min) in a double-blind randomized crossover design. Glucose (45 g), together with 5 g 3-O-methylglucose (3-OMG) and 20 MBq (99m)Tc-sulfur colloid (total volume 200 mL), was given intraduodenally (t = 0-60 min; 3 kcal/min). Duodenal motility and flow were measured using a combined manometry-impedance catheter and small intestinal transit using scintigraphy. In both groups, duodenal pressure waves and antegrade flow events were fewer, and transit was slower with exenatide, as were the areas under the curves for serum 3-OMG and blood glucose concentrations. Insulin concentrations were initially lower with exenatide than with saline and subsequently higher. Nausea was greater in both groups with exenatide, but suppression of small intestinal motility and flow was observed even in subjects with little or no nausea. The inhibition of small intestinal motor function represents a novel mechanism by which exenatide can attenuate postprandial glycemia.en
dc.description.statementofresponsibilitySony S. Thazhath, Chinmay S. Marathe, Tongzhi Wu, Jessica Chang, Joan Khoo, Paul Kuo, Helen L. Checklin, Michelle J. Bound, Rachael S. Rigda, Benjamin Crouch, Karen L. Jones, Michael Horowitz, and Christopher K. Rayneren
dc.publisherAmerican Diabetes Associationen
dc.rights© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.en
dc.subjectGlucose; peptidesen
dc.titleThe glucagon-like peptide 1 receptor agonist exenatide inhibits small intestinal motility, flow, transit, and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomized controlled trialen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidWu, T. [0000-0003-1656-9210]en
dc.identifier.orcidRigda, R. [0000-0002-8924-5359]en
dc.identifier.orcidJones, K. [0000-0002-1155-5816]en
dc.identifier.orcidHorowitz, M. [0000-0002-0942-0306]en
dc.identifier.orcidRayner, C. [0000-0002-5527-256X]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.